Report Details:
15 Companies Covered
128 Pages
Market Research Future (MRFR) has published on the “Global Single Cell Multi-Omics Market”.
The Single Cell Multi-Omics market is estimated to register a CAGR of 22.00%during the forecast period of 2024 to 2032.
MRFR recognizes the following companies as the key players in the global Single Cell Multi-Omics market—CELLENION, PerkinElmer Inc., 10x Genomics, ANGLE plc, Illumina, Inc., Bio-Rad Laboratories, Inc.
Market Highlights
The global Single Cell Multi-Omicsmarketis accounted to register a CAGR of22.00%during the forecast period and is estimated to reach USD 10.2 billion by 2032.
The customer base for singlecell multi-omics is expanding due to a number of variables, one of which is the growing need for tailored therapy. Molecular analysis of individual cells can shed light on the underlying causes of disease and help develop more specialized and targeted treatments. The identification of biomarkers for illness diagnosis, prognosis and therapy response can be aided by singlecell multi-omics. This may result in the creation of novel treatments and diagnostic tools. Singlecell multi-omics can assist in locating novel therapeutic targets and routes.
Access Full Report @ https://www.marketresearchfuture.com/reports/single-cell-multi-omics-market-21844
Segment Analysis
The global Single Cell Multi-Omics markethas been segmented based on Product, Application and End-user.
On the basis of product, the market is segmented into Single-Cell Genomics, Single-Cell Proteomics, Single-Cell Metabolomics and Single-Cell Transcriptomics. The Single-Cell Genomics segment was attributed to holding the largest market share in 2023. This is due to the fact that it makes it feasible to find rare cell types and biomarkers that bulk sequencing might miss.
Based on application, the global Single Cell Multi-Omics market has been segmented into Immunology, Cell Biology, Oncology and Neurology. The Oncology segment was expected to hold the largest market share in 2023.This is a result of the sector's investments in high-value indications and underserved patient populations through medication development and research.
Based on end-use, the global Single Cell Multi-Omics market has been segmented into Hospital and Diagnostic Laboratories, Academic and Research Organizations, Pharmaceutical & Biotechnology Companies and Others. The Academic and Research Organizationssegment was expected to hold the largest market share in 2023.This is due to the fact that they often act as catalysts for the development of cutting-edge singlecellmulti-omics methods and technologies.
Regional Analysis
The global Single Cell Multi-Omics market, based on region, has been divided into North America, Europe, Asia-Pacific and Rest of the World. North America consists of US and Canada. The Europe Single Cell Multi-Omics market comprises of Germany, France, the UK, Italy, Spain and the rest of Europe. The Single Cell Multi-Omics market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea and the rest of Asia-Pacific. The Rest of the World Single Cell Multi-Omics market comprises of Middle East, Africa and Latin America.
The largest market share for Single Cell Multi-Omics was maintained by the North American regional sector.This isbecause the Global sales of Single Cell Multi-Omics are dominated by North America. North America has a strong infrastructure for research and development, including prestigious colleges, research centers, and pharmaceutical firms. Due to the significant investments made by these universities in single-cell microscopic techniques, North America is now a center for innovation and development. Significant funds have been allocated by the US government to biotechnology research, including single-cell omics. The National Institutes of Health describes a high-throughput automated approach for producing protein therapeutic production cell lines.
Moreover, the Europe market has been persistently growing over the forecast period. The demand for significant funding for life sciences research, including single-cell multi-omics studies, is coming from European governments, universities and private investors. Market expansion is being facilitated by funding programs designed to foster creative research endeavors and partnerships.
Additionally, the Single Cell Multi-Omics market in the Asia Pacific area has been expanding quickly for a number of reasons. These nations have made significant investments in the study and creation of novel technologies, such as singlecell multi-omics, which has increased consumer demand for these goods. Second, single-cell analysis is needed for individualized medication, which is becoming more and more necessary in the region due to the rising prevalence of chronic diseases, including cancer and neurological disorders.
Furthermore, the rest of the world's Single Cell Multi-Omics market is divided into the Middle East, Africa and Latin America. The growth in the market is due to the expansion of Single Cell Multi-Omics due to a number of variables, one of which is the growing need for tailored therapy. Government support, a rise in investor interest and the viability of the technology in the sector are all contributing factors to the market expansion.
Key Findings of the Study
- The global Single Cell Multi-Omics market is expected to reach USD 10.2billion by 2032, at a CAGR of 22.00% during the forecast period.
- The Asia-Pacific region accounted for the fastest-growing global marketas the nations have made significant investments in the study and creation of novel technologies, such as singlecell multi-omics.
-
Based on application, theOncology segment was expected to hold the largest market share in 2023. - CELLENION, PerkinElmer Inc., 10x Genomics, ANGLE plc, Illumina, Inc., and Bio-Rad Laboratories, Inc.are the key market players.